Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin
Autor(a) principal: | |
---|---|
Data de Publicação: | 2005 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442005000400005 |
Resumo: | INTRODUCTION: Treatment with recombinant human erythropoietin (rHuEpo) is associated with an improvement in well-being and quality of life in patients submitted to maintenance hemodialysis (HD). OBJECTIVES: The goal of this work was to evaluate the levels of sex hormones, hematocrit, albumin and zinc in HD patients with rHuEpo therapy and compare them with those observed in patients without rHuEpo treatment. MATERIAL AND METHODS: Two groups of twelve male HD patients each were selected for a transversal study; one did not receive rHuEpo (group 1) whereas the other one did (group 2). Levels of hematocrit, albumin, zinc, luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, and testosterone were determined. RESULTS: Group 2 patients showed significantly higher medians (p < 0.05) of testosterone (4.65 vs. 3.5ng/mL), hematocrit (30.5 vs. 22%), albumin (3,9 vs. 3,7g/dL) and zinc (62.5 vs. 50.5microg/dL) than group 1 patients. DISCUSSION: In this study rHuEpo treatment resulted in higher hematocrit, testosterone, zinc and albumin. It is suggested that, in patients recipients of rHuEpo, higher levels of zinc and testosterone may be factors that contribute to relieve sexual dysfunction and improve quality of life. CONCLUSIONS: In HD patients, hematocrit, albumin, serum zinc and testosterone levels were higher in rHuEpo recipients when compared with patients not receiving this hormone therapy. |
id |
SBP-1_1b2f94bab08ee4dcd1b3728fbbc3c729 |
---|---|
oai_identifier_str |
oai:scielo:S1676-24442005000400005 |
network_acronym_str |
SBP-1 |
network_name_str |
Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) |
repository_id_str |
|
spelling |
Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietinHemodialysisErythropoietinHematocritAlbuminTestosteroneZincINTRODUCTION: Treatment with recombinant human erythropoietin (rHuEpo) is associated with an improvement in well-being and quality of life in patients submitted to maintenance hemodialysis (HD). OBJECTIVES: The goal of this work was to evaluate the levels of sex hormones, hematocrit, albumin and zinc in HD patients with rHuEpo therapy and compare them with those observed in patients without rHuEpo treatment. MATERIAL AND METHODS: Two groups of twelve male HD patients each were selected for a transversal study; one did not receive rHuEpo (group 1) whereas the other one did (group 2). Levels of hematocrit, albumin, zinc, luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, and testosterone were determined. RESULTS: Group 2 patients showed significantly higher medians (p < 0.05) of testosterone (4.65 vs. 3.5ng/mL), hematocrit (30.5 vs. 22%), albumin (3,9 vs. 3,7g/dL) and zinc (62.5 vs. 50.5microg/dL) than group 1 patients. DISCUSSION: In this study rHuEpo treatment resulted in higher hematocrit, testosterone, zinc and albumin. It is suggested that, in patients recipients of rHuEpo, higher levels of zinc and testosterone may be factors that contribute to relieve sexual dysfunction and improve quality of life. CONCLUSIONS: In HD patients, hematocrit, albumin, serum zinc and testosterone levels were higher in rHuEpo recipients when compared with patients not receiving this hormone therapy.Sociedade Brasileira de Patologia Clínica2005-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442005000400005Jornal Brasileiro de Patologia e Medicina Laboratorial v.41 n.4 2005reponame:Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)instname:Sociedade Brasileira de Patologia (SBP)instacron:SBP10.1590/S1676-24442005000400005info:eu-repo/semantics/openAccessSchleicher,Maria MouranildaMoura,Flávio José Dutra deDiniz,Enzio Galvão Torreão BrazSchleicher,Carlos CésarRosa,Tânia TorresDorea,José GarrofeVeiga,Joel Paulo Russomanoeng2005-10-25T00:00:00Zoai:scielo:S1676-24442005000400005Revistahttp://www.scielo.br/jbpmlhttps://old.scielo.br/oai/scielo-oai.php||jbpml@sbpc.org.br1678-47741676-2444opendoar:2005-10-25T00:00Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) - Sociedade Brasileira de Patologia (SBP)false |
dc.title.none.fl_str_mv |
Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin |
title |
Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin |
spellingShingle |
Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin Schleicher,Maria Mouranilda Hemodialysis Erythropoietin Hematocrit Albumin Testosterone Zinc |
title_short |
Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin |
title_full |
Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin |
title_fullStr |
Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin |
title_full_unstemmed |
Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin |
title_sort |
Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin |
author |
Schleicher,Maria Mouranilda |
author_facet |
Schleicher,Maria Mouranilda Moura,Flávio José Dutra de Diniz,Enzio Galvão Torreão Braz Schleicher,Carlos César Rosa,Tânia Torres Dorea,José Garrofe Veiga,Joel Paulo Russomano |
author_role |
author |
author2 |
Moura,Flávio José Dutra de Diniz,Enzio Galvão Torreão Braz Schleicher,Carlos César Rosa,Tânia Torres Dorea,José Garrofe Veiga,Joel Paulo Russomano |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Schleicher,Maria Mouranilda Moura,Flávio José Dutra de Diniz,Enzio Galvão Torreão Braz Schleicher,Carlos César Rosa,Tânia Torres Dorea,José Garrofe Veiga,Joel Paulo Russomano |
dc.subject.por.fl_str_mv |
Hemodialysis Erythropoietin Hematocrit Albumin Testosterone Zinc |
topic |
Hemodialysis Erythropoietin Hematocrit Albumin Testosterone Zinc |
description |
INTRODUCTION: Treatment with recombinant human erythropoietin (rHuEpo) is associated with an improvement in well-being and quality of life in patients submitted to maintenance hemodialysis (HD). OBJECTIVES: The goal of this work was to evaluate the levels of sex hormones, hematocrit, albumin and zinc in HD patients with rHuEpo therapy and compare them with those observed in patients without rHuEpo treatment. MATERIAL AND METHODS: Two groups of twelve male HD patients each were selected for a transversal study; one did not receive rHuEpo (group 1) whereas the other one did (group 2). Levels of hematocrit, albumin, zinc, luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, and testosterone were determined. RESULTS: Group 2 patients showed significantly higher medians (p < 0.05) of testosterone (4.65 vs. 3.5ng/mL), hematocrit (30.5 vs. 22%), albumin (3,9 vs. 3,7g/dL) and zinc (62.5 vs. 50.5microg/dL) than group 1 patients. DISCUSSION: In this study rHuEpo treatment resulted in higher hematocrit, testosterone, zinc and albumin. It is suggested that, in patients recipients of rHuEpo, higher levels of zinc and testosterone may be factors that contribute to relieve sexual dysfunction and improve quality of life. CONCLUSIONS: In HD patients, hematocrit, albumin, serum zinc and testosterone levels were higher in rHuEpo recipients when compared with patients not receiving this hormone therapy. |
publishDate |
2005 |
dc.date.none.fl_str_mv |
2005-08-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442005000400005 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442005000400005 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1676-24442005000400005 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Patologia Clínica |
publisher.none.fl_str_mv |
Sociedade Brasileira de Patologia Clínica |
dc.source.none.fl_str_mv |
Jornal Brasileiro de Patologia e Medicina Laboratorial v.41 n.4 2005 reponame:Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) instname:Sociedade Brasileira de Patologia (SBP) instacron:SBP |
instname_str |
Sociedade Brasileira de Patologia (SBP) |
instacron_str |
SBP |
institution |
SBP |
reponame_str |
Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) |
collection |
Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) |
repository.name.fl_str_mv |
Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) - Sociedade Brasileira de Patologia (SBP) |
repository.mail.fl_str_mv |
||jbpml@sbpc.org.br |
_version_ |
1752122293703671808 |